203 related articles for article (PubMed ID: 36142613)
21. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
22. NIS and epithelial-mesenchymal transition marker expression of circulating tumor cells for predicting and monitoring the radioactive iodine-131 therapy effect in differentiated thyroid cancers.
Zheng L; Wang G; Guo W; Pan D; Xie L; He S; Luo C; Li H; Ran Y; Wu S; Liu F; Zhang X; Huang D
Mol Biol Rep; 2019 Aug; 46(4):4201-4212. PubMed ID: 31147861
[TBL] [Abstract][Full Text] [Related]
23. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
[TBL] [Abstract][Full Text] [Related]
24. Digitalislike Compounds Restore hNIS Expression and Iodide Uptake Capacity in Anaplastic Thyroid Cancer.
Tesselaar MH; Crezee T; Schuurmans I; Gerrits D; Nagarajah J; Boerman OC; van Engen-van Grunsven I; Smit JWA; Netea-Maier RT; Plantinga TS
J Nucl Med; 2018 May; 59(5):780-786. PubMed ID: 29242405
[TBL] [Abstract][Full Text] [Related]
25. Modulation of sodium iodide symporter in thyroid cancer.
Lakshmanan A; Scarberry D; Shen DH; Jhiang SM
Horm Cancer; 2014 Dec; 5(6):363-73. PubMed ID: 25234361
[TBL] [Abstract][Full Text] [Related]
26. Post-translational Regulation of Radioactive Iodine Therapy Response in Papillary Thyroid Carcinoma.
Amit M; Na'ara S; Francis D; Matanis W; Zolotov S; Eisenhaber B; Eisenhaber F; Weiler Sagie M; Malkin L; Billan S; Charas T; Gil Z
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 30053080
[TBL] [Abstract][Full Text] [Related]
27. The role of miR-139-5p in radioiodine-resistant thyroid cancer.
Pecce V; Sponziello M; Verrienti A; Grani G; Abballe L; Bini S; Annunziata S; Perotti G; Salvatori M; Zagaria L; Maggisano V; Russo D; Filetti S; Durante C
J Endocrinol Invest; 2023 Oct; 46(10):2079-2093. PubMed ID: 36933170
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Combination Therapy with Lenvatinib and Radioactive Iodine in Thyroid Cancer Preclinical Model.
Suzuki K; Iwai H; Utsunomiya K; Kono Y; Watabe T; Kobayashi Y; Bui DV; Sawada S; Yun Y; Mitani A; Fukui K; Sakai H; Chu HH; Linh NM; Tanigawa N; Kanda A
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077268
[TBL] [Abstract][Full Text] [Related]
29. Synergic radiosensitization of sinomenine hydrochloride and radioiodine on human papillary thyroid carcinoma cells.
Zhao A; Zhang J; Liu Y; Jia X; Lu X; Wang Q; Ji T; Yang L; Xue J; Gao R; Yu Y; Yang A
Transl Oncol; 2021 Oct; 14(10):101172. PubMed ID: 34243014
[TBL] [Abstract][Full Text] [Related]
30. HIF-1α/YAP Signaling Rewrites Glucose/Iodine Metabolism Program to Promote Papillary Thyroid Cancer Progression.
Song H; Qiu Z; Wang Y; Xi C; Zhang G; Sun Z; Luo Q; Shen C
Int J Biol Sci; 2023; 19(1):225-241. PubMed ID: 36594102
[No Abstract] [Full Text] [Related]
31. Methylation status of genes in papillary thyroid carcinoma.
Smith JA; Fan CY; Zou C; Bodenner D; Kokoska MS
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1006-11. PubMed ID: 17938324
[TBL] [Abstract][Full Text] [Related]
32. Gut Microbiome and Radioiodine-Refractory Papillary Thyroid Carcinoma Pathophysiology.
Samimi H; Haghpanah V
Trends Endocrinol Metab; 2020 Sep; 31(9):627-630. PubMed ID: 32273149
[TBL] [Abstract][Full Text] [Related]
33. Targeting GLI1 Transcription Factor for Restoring Iodine Avidity with Redifferentiation in Radioactive-Iodine Refractory Thyroid Cancers.
Oh JM; Rajendran RL; Gangadaran P; Hong CM; Jeong JH; Lee J; Ahn BC
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406554
[TBL] [Abstract][Full Text] [Related]
34. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism.
Filetti S; Bidart JM; Arturi F; Caillou B; Russo D; Schlumberger M
Eur J Endocrinol; 1999 Nov; 141(5):443-57. PubMed ID: 10576759
[TBL] [Abstract][Full Text] [Related]
35. Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro.
Ullmann TM; Liang H; Moore MD; Al-Jamed I; Gray KD; Limberg J; Stefanova D; Buicko JL; Finnerty B; Beninato T; Zarnegar R; Min IM; Fahey TJ
Surgery; 2020 Jan; 167(1):56-63. PubMed ID: 31585718
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of Rap1GAP Expression Activates the TGF-
Yan Z; Yangyanqiu W; Shuwen H; Jing M; Haihong L; Gong C; Yin J; Qing Z; Weili G
Biomed Res Int; 2021; 2021():6840642. PubMed ID: 34840979
[TBL] [Abstract][Full Text] [Related]
37. Redox Homeostasis in Thyroid Cancer: Implications in Na
Cazarin J; Dupuy C; Pires de Carvalho D
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682803
[TBL] [Abstract][Full Text] [Related]
38. Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells.
Kogai T; Sajid-Crockett S; Newmarch LS; Liu YY; Brent GA
J Endocrinol; 2008 Nov; 199(2):243-52. PubMed ID: 18762555
[TBL] [Abstract][Full Text] [Related]
39. MiR-181a-5p Regulates NIS Expression in Papillary Thyroid Carcinoma.
Gierlikowski W; Broniarek K; Cheda Ł; Rogulski Z; Kotlarek-Łysakowska M
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199867
[TBL] [Abstract][Full Text] [Related]
40. Characterization of thyroid-stimulating blocking antibodies that appeared during transient hypothyroidism after radioactive iodine therapy.
Kung AW; Lau KS; Kohn LD
Thyroid; 2000 Oct; 10(10):909-17. PubMed ID: 11081257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]